Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$70.30

1.73 (2.52%)

, MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

07:37
10/06/16
10/06
07:37
10/06/16
07:37

Alnylam news not a negative read through on other RNAi drugs, says RBC Capital

After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, RBC Capital analyst Michael Yee does not thinks that the news indicates problems with all RNAi drugs. Rather, he thinks that RNAi was not the proper treatment for the disease that Alnylam was targeting. Other companies with RNAi treatments include The Medicines Company (MDCO0, Ionis Pharmaceuticals (IONS), Arrowhead (ARWR), and Arbutus Biopharma (ABUS).

ALNY

Alnylam

$70.30

1.73 (2.52%)

MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

IONS

Ionis Pharmaceuticals

$36.38

0.72 (2.02%)

ARWR

Arrowhead

$7.52

0.23 (3.16%)

ABUS

Arbutus Biopharma

$3.50

0.125 (3.71%)

  • 07

    Oct

  • 14

    Oct

  • 06

    Nov

ALNY Alnylam
$70.30

1.73 (2.52%)

10/06/16
LEER
10/06/16
DOWNGRADE
Target $40
LEER
Market Perform
Alnylam downgraded to Market Perform from Outperform at Leerink
Leerink analyst Michael Schmidt downgraded Alnylam Pharmaceuticals to Market Perform after the company discontinued development of revusiran. To reflect an increased level of uncertainty around the company's pipeline, the analyst cut his price target for the shares to $40 from $107. JPMorgan and Barclays also downgraded Alnylam this morning while Piper Jaffray recommends buying the stock on weakness.
10/06/16
JEFF
10/06/16
NO CHANGE
Target $43
JEFF
Buy
Alnylam setback has no read-through to Medicines Co., says Jefferies
Jefferies analyst Biren Amin believes Alnylam Pharmaceuticals' (ALNY) decision to stop revusiran due to lack of a treatment benefit has no read-through to The Medicines Co.'s (MDCO) PCSK9 program. Amin keeps a Buy rating on Medicines Co. with a $43 price target.
10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,
10/06/16
JEFF
10/06/16
NO CHANGE
Target $58
JEFF
Buy
Alnylam price target lowered to $58 from $86 at Jefferies
Jefferies analyst Gena Wang lowered her price target for Alnylam Pharmaceuticals to $58 from $86 following the termination of revusiran Phase 3 due to mortality imbalance. The analyst believes the setback, while "major," is likely to be program specific and not impact the company's other trials. She keeps a Buy rating on Alnylam.
MDCO The Medicines Co.
$38.51

0.32 (0.84%)

09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
07/11/16
JEFF
07/11/16
NO CHANGE
Target $43
JEFF
Buy
Jefferies views The Medicines Co. ruling as positive surprise
Jefferies analyst Biren Amin views today's Court of Appeals ruling as a "positive surprise" for The Medicines Company. The ruling "breathes potential life" into the company's Angiomax patents, Amin tells investors in a research note. He expects Hospira to file an appeal within 90 days. The analyst has a Buy rating on The Medicines Co. with a $43 price target.
08/02/16
EVER
08/02/16
NO CHANGE
EVER
Buy
Pfizer shelves oral PCSK9, a Medicines Co. competitor, says Evercore ISI
Evercore ISI analyst Umer Raffat said Pfizer (PFE) management does not thin the profile for oral PCSK9 will be competitive with the strong efficacy of antibodies and have moved other interesting products forward. Raffat said some Medicines Co. (MDCO) investors had worried that a potential oral PCSk9 from Pfizer could greatly reduce enthusiasm for an every-6-month PCSk9 from MDCO. The analyst said the next catalyst for The Medicines Co. is A1 Milano readout this month. Raffat rates The Medicines Co. a Buy with a $52 price target.
IONS Ionis Pharmaceuticals
$36.38

0.72 (2.02%)

09/28/16
JANY
09/28/16
INITIATION
Target $47
JANY
Buy
Ionis Pharmaceuticals initiated with a Buy at Janney Capital
Janney Capital analyst Roy Buchanan initiated Ionis Pharmaceuticals with a Buy and a $47 fair value estimate. Buchanan believes the late stage pipeline, including wholly-owned volanesorsen, and the base technology can add meaningful value to Ionis. 1H 2017 is particularly rich with 3 phase 3 readouts, with potential for another early, interim look at SMA.
10/06/16
BMOC
10/06/16
UPGRADE
BMOC
Outperform
Ionis Pharmaceuticals upgraded to Outperform from Market Perform at BMO Capital
10/04/16
RBCM
10/04/16
NO CHANGE
Target $375
RBCM
Outperform
Biogen could rise $20 or more per share on SMA success, says RBC Capital
RBC Capital analyst Michael Yee expects the first presentation of data from Biogen's (BIIB) Phase III ENDEAR trial studying nusinersen, an investigational treatment for spinal muscular atrophy, or SMA, this week, potentially during the late breaker session at the WMS Congress on October 8. Biogen and partner Ionis Pharmaceuticals (IONS) already announced in August that the study in Type I infants hit the interim analysis and stopped early for positive data. The much larger opportunity in older children has data expected to read out in Spring 2017, noted Yee, who thinks Biogen can have upside from $10 to over $20 per share based on its SMA opportunity. Yee keeps an Outperform rating and $375 price target on Biogen shares.
ARWR Arrowhead
$7.52

0.23 (3.16%)

08/18/16
08/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Barnes & Noble (BKS) initiated with a Neutral at Sidoti. 2. Digital Ally (DGLY) initiated with a Buy at Maxim. 3. Korn/Ferry (KFY) initiated with a Hold at Deutsche Bank. 4. Phillips 66 Partners (PSXP) initiated with a Buy at Stifel. 5. Arrowhead (ARWR) initiated with a Buy at Cantor. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/19/16
WBLR
08/19/16
INITIATION
Target $9
WBLR
Outperform
Arrowhead initiated with an Outperform at William Blair
William Blair analyst Y. Katherine Xu started Arrowhead Pharmaceuticals with an Outperform rating and $9 price target.
08/17/16
CANT
08/17/16
INITIATION
Target $15
CANT
Buy
Arrowhead initiated with a Buy at Cantor
Target $15.
09/29/16
PIPR
09/29/16
NO CHANGE
Target $10
PIPR
Overweight
Arrowhead price target raised to $10 from $8 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals (ARWR) to $10 after the company licensed two preclinical cardiovascular RNAi drugs with Amgen (AMGN). Amgen is the "ideal partner" and Arrowhead's balance sheet is now "meaningfully" strengthened, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Arrowhead.
ABUS Arbutus Biopharma
$3.50

0.125 (3.71%)

08/19/16
08/19/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aratana Therapeutics (PETX) assumed with a Buy at Jefferies. 2. Arbutus Biopharma (ABUS) initiated with an Outperform at William Blair. 3. Acceleron (XLRN) initiated with a Buy at BTIG. 4. Agios Pharmaceuticals (AGIO) initiated with a Neutral at BTIG. 5. Suncor (SU) reinstated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/19/16
WBLR
08/19/16
INITIATION
Target $7
WBLR
Outperform
Arbutus Biopharma initiated with an Outperform at William Blair
William Blair analyst Y. Katherine Xu started Arbutus Biopharma with an Outperform rating and $7 price target.
08/05/16
LEER
08/05/16
DOWNGRADE
LEER
Market Perform
Arbutus Biopharma downgraded to Market Perform from Outperform at Leerink
07/08/16
CHDN
07/08/16
DOWNGRADE
CHDN
Sell
Arbutus Biopharma downgraded to Sell from Neutral at Chardan

TODAY'S FREE FLY STORIES

VNR

Vanguard Natural

$1.12

0.1083 (10.72%)

06:35
12/09/16
12/09
06:35
12/09/16
06:35
Downgrade
Vanguard Natural rating change  »

Vanguard Natural…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HDSN

Hudson Technologies

$7.33

0.01 (0.14%)

06:35
12/09/16
12/09
06:35
12/09/16
06:35
Syndicate
Hudson Technologies 6.429M share Secondary priced at $7.00 »

William Blair and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 09

    Dec

NVCR

Novocure

$8.75

0.4 (4.79%)

06:34
12/09/16
12/09
06:34
12/09/16
06:34
Conference/Events
Novocure to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

LFUS

Littelfuse

$154.58

3.1 (2.05%)

06:33
12/09/16
12/09
06:33
12/09/16
06:33
Earnings
Littelfuse backs Q4 adjusted EPS view $1.45-$1.59, consensus $1.52 »

Backs Q4 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

FLR

Fluor

$56.00

1.33 (2.43%)

06:32
12/09/16
12/09
06:32
12/09/16
06:32
Upgrade
Fluor rating change  »

Fluor upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIMO

Gigamon

$47.95

-0.4 (-0.83%)

06:32
12/09/16
12/09
06:32
12/09/16
06:32
Upgrade
Gigamon rating change  »

Gigamon upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WNC

Wabash

$15.13

0.44 (3.00%)

06:32
12/09/16
12/09
06:32
12/09/16
06:32
Initiation
Wabash initiated  »

Wabash initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PH

Parker-Hannifin

$141.89

-3.09 (-2.13%)

06:32
12/09/16
12/09
06:32
12/09/16
06:32
Initiation
Parker-Hannifin initiated  »

Parker-Hannifin initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDAIF

Daimler AG

$72.20

0.19 (0.26%)

, VLKAY

Volkswagen

$28.75

-0.188 (-0.65%)

06:32
12/09/16
12/09
06:32
12/09/16
06:32
Periodicals
Daimler CEO says company will be 2016's biggest luxury carmaker, Reuters says »

Daimler CEO Dieter…

DDAIF

Daimler AG

$72.20

0.19 (0.26%)

VLKAY

Volkswagen

$28.75

-0.188 (-0.65%)

BMWYY

BMW

$31.39

0.205 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

  • 10

    Jan

GWR

Genesee & Wyoming

$79.54

1.77 (2.28%)

06:31
12/09/16
12/09
06:31
12/09/16
06:31
Hot Stocks
Genesee & Wyoming reports November traffic up 3.7% y/y »

Genesee & Wyoming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DTEA

DAVIDsTEA

$9.30

0.15 (1.64%)

06:30
12/09/16
12/09
06:30
12/09/16
06:30
Downgrade
DAVIDsTEA rating change  »

DAVIDsTEA downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WCN

Waste Connections

$76.63

0.04 (0.05%)

06:29
12/09/16
12/09
06:29
12/09/16
06:29
Upgrade
Waste Connections rating change  »

Waste Connections…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPR

Spirit AeroSystems

$61.26

0.65 (1.07%)

06:28
12/09/16
12/09
06:28
12/09/16
06:28
Downgrade
Spirit AeroSystems rating change  »

Spirit AeroSystems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADSK

Autodesk

$81.74

1.4 (1.74%)

06:26
12/09/16
12/09
06:26
12/09/16
06:26
Upgrade
Autodesk rating change  »

Autodesk upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

WEGRY

Weir Group

$11.65

-0.08 (-0.68%)

06:26
12/09/16
12/09
06:26
12/09/16
06:26
Downgrade
Weir Group rating change  »

Weir Group downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVRR

CVR Refining

$10.40

1.25 (13.66%)

06:25
12/09/16
12/09
06:25
12/09/16
06:25
Upgrade
CVR Refining rating change  »

CVR Refining upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCS

Barclays

$11.99

0.09 (0.76%)

06:25
12/09/16
12/09
06:25
12/09/16
06:25
Downgrade
Barclays rating change  »

Barclays downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCAR

PACCAR

$68.07

0.44 (0.65%)

06:24
12/09/16
12/09
06:24
12/09/16
06:24
Upgrade
PACCAR rating change  »

PACCAR upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSK

Oshkosh

$71.48

-0.07 (-0.10%)

06:23
12/09/16
12/09
06:23
12/09/16
06:23
Downgrade
Oshkosh rating change  »

Oshkosh downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTW

Manitowoc

$6.18

0.07 (1.15%)

06:22
12/09/16
12/09
06:22
12/09/16
06:22
Downgrade
Manitowoc rating change  »

Manitowoc downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMT

Kennametal

$34.21

0.16 (0.47%)

06:21
12/09/16
12/09
06:21
12/09/16
06:21
Downgrade
Kennametal rating change  »

Kennametal downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$57.29

0.01 (0.02%)

06:20
12/09/16
12/09
06:20
12/09/16
06:20
Periodicals
Wells Fargo names four board members for sales scandal review, Reuters reports »

Wells Fargo named…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNCFF

UniCredit

$2.73

0.07 (2.63%)

06:20
12/09/16
12/09
06:20
12/09/16
06:20
Hot Stocks
UniCredit to sell 32.8% stake in Bank Pekao to PZN, PFR »

UniCredit announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETN

Eaton

$68.98

0.08 (0.12%)

06:19
12/09/16
12/09
06:19
12/09/16
06:19
Upgrade
Eaton rating change  »

Eaton upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSGN

MSG Networks

$21.20

-0.45 (-2.08%)

06:18
12/09/16
12/09
06:18
12/09/16
06:18
Upgrade
MSG Networks rating change  »

MSG Networks upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.